Vimarsana
Biggest News Aggregation in the World

Yaron Werber News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Yaron Werber. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Yaron Werber Today - Breaking & Trending Today

BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript - Vimarsana News

BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript

BNTX earnings call for the period ending March 31, 2024.

Source: fool.com
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript - Vimarsana News

Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript

Genmab A/S reports earnings inline with expectations. Reported EPS is $0.16 EPS, expectations were $0.16.

Exelixis (EXEL) Q1 2024 Earnings Call Transcript - Vimarsana News

Exelixis (EXEL) Q1 2024 Earnings Call Transcript

EXEL earnings call for the period ending March 31, 2024.

Source: fool.com
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Earnings Call Transcript - Vimarsana News

Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Earnings Call Transcript

Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.3 EPS, expectations were $-0.27. Roivant Sciences Ltd.

SpringWorks' Noncancerous Tumor Drug to Cost $29,000 Per Month - Vimarsana News

SpringWorks' Noncancerous Tumor Drug to Cost $29,000 Per Month

SpringWorks Therapeutics' drug for treating adult patients with a type of rare noncancerous soft-tissue tumor will be sold in the US at a list price of $29,000 for a 30-day supply.